Mevalonate pathway: A review of clinical and therapeutical implications

Clinical Biochemistry

Volumn 40, Issue 9-10, 2007, Pages 575-584

  Buhaescu, Irina ^a   Izzedine, Hassane ^b  

^a SAINT VINCENT HOSPITAL   (United States)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Bisphosphonates; Isoprenoids; Mevalonate kinase deficiency; Mevalonate pathway; Statins

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CHOLESTEROL; DOLICHOL; GERANYLTRANSFERASE; GGTI DU 40; HEME DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INCADRONIC ACID; ISOPRENOID; L 778123; LONAFARNIB; MEVALONATE KINASE; MEVALONIC ACID; PAMIDRONIC ACID; PLACEBO; PRAVASTATIN; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RISEDRONIC ACID; SIMVASTATIN; TIPIFARNIB; TRANSFER RNA; TRANSFERASE INHIBITOR; UBIQUINONE; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ACIDURIA; ALZHEIMER DISEASE; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; AUTOINFLAMMATORY DISEASE; BIOSYNTHESIS; BREAST TUMOR; CANCER INCIDENCE; CARDIOVASCULAR DISEASE; CELL ACTIVITY; CELL DIFFERENTIATION; CELL GROWTH; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; ENZYME DEFICIENCY; GASTROINTESTINAL TUMOR; GENE MUTATION; HUMAN; HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME; METABOLIC BONE DISEASE; METABOLISM; ONCOLOGY; PLEIOTROPY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

ANTINEOPLASTIC AGENTS; DIPHOSPHONATES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPID METABOLISM DISORDERS; LIPID METABOLISM, INBORN ERRORS; METABOLIC NETWORKS AND PATHWAYS; MEVALONIC ACID; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR);

EID: 34249685010     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2007.03.016     Document Type: Review

References (133)

1. Goldstein J.L., and Brown M.S. Regulation of the mevalonate pathway. Nature 343 6257 (1990) 425-430
2. Hinson D.D., Chambliss K.L., Toth M.J., Tanaka R.D., and Gibson K.M. Post-translational regulation of mevalonate kinase by intermediates of the cholesterol and nonsterol isoprene biosynthetic pathways. J. Lipid Res. 38 11 (1997) 2216-2223
3. Horton J.D. Sterol regulatory element-binding proteins: transcriptional activators of lipid synthesis. Biochem. Soc. Trans. 30 Pt. 6 (2002) 1091-1095
4. Weber L.W., Boll M., and Stampfl A. Maintaining cholesterol homeostasis: sterol regulatory element-binding proteins. World J. Gastroenterol. 10 21 (2004) 3081-3087
5. Sakakura Y., Shimano H., and Sone H. Sterol regulatory element-binding proteins induce an entire pathway of cholesterol synthesis. Biochem. Biophys. Res. Commun. 286 1 (2001) 176-183
6. Bonetti P.O., Lerman L.O., Napoli C., and Lerman A. Statin effects beyond lipid lowering - are they clinically relevant?. Eur. Heart J. 24 3 (2003) 225-248
7. Edwards P.A., and Ericsson J. Sterols and isoprenoids: signaling molecules derived from the cholesterol biosynthetic pathway. Annu. Rev. Biochem. 68 (1999) 157-185
8. Drenth J.P., Haagsma C.J., and van der Meer J.W. Hyperimmunoglobulinemia D and periodic fever syndrome. The clinical spectrum in a series of 50 patients. Int. Hyper-IgD Study Group Med. (Baltimore) 73 3 (1994) 133-144
9. Hoffmann G.F., Charpentier C., Mayatepek E., et al. Clinical and biochemical phenotype in 11 patients with mevalonic aciduria. Pediatrics 91 5 (1993) 915-921
10. Frenkel J., Houten S.M., Waterham H.R., et al. Clinical and molecular variability in childhood periodic fever with hyperimmunoglobulinaemia D. Rheumatology (Oxford) 40 5 (2001) 579-584
11. Haas D., and Hoffmann G.F. Mevalonate kinase deficiencies: from mevalonic aciduria to hyperimmunoglobulinemia D syndrome. Orphanet J. Rare Dis. 1 1 (2006) 13
12. Obici L., Manno C., and Muda A.O. First report of systemic reactive (AA) amyloidosis in a patient with the hyperimmunoglobulinemia D with periodic fever syndrome. Arthritis Rheum 50 9 (2004) 2966-2969
13. Lachmann H.J., Goodman H.J., Andrews P.A., et al. AA amyloidosis complicating hyperimmunoglobulinemia D with periodic fever syndrome: a report of two cases. Arthritis Rheum 54 6 (2006) 2010-2014
14. Houten S.M., Kuis W., Duran M., et al. Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome. Nat. Genet. 22 2 (1999) 175-177
15. Drenth J.P., Cuisset L., Grateau G., et al. Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper-IgD Study Group. Nat. Genet. 22 2 (1999) 178-181
16. Houten S.M., Schneiders M.S., Wanders R.J., and Waterham H.R. Regulation of isoprenoid/cholesterol biosynthesis in cells from mevalonate kinase-deficient patients. J. Biol. Chem. 278 8 (2003) 5736-5743
17. Gibson K.M., Lohr J.L., Broock R.L., et al. Mevalonate kinase in lysates of cultured human fibroblasts and lymphoblasts: kinetic properties, assay conditions, carrier detection and measurement of residual activity in a patient with mevalonic aciduria. Enzyme 41 (1989) 47-55
18. Frenkel J., Willemsen M.A., Weemaes C.M., Dorland L., and Mayatepek E. Increased urinary leukotriene E(4) during febrile attacks in the hyperimmunoglobulinaemia D and periodic fever syndrome. Arch. Dis. Child 85 (2001) 158-159
19. Frenkel J., Rijkers G.T., Mandey S.H., et al. Lack of isoprenoid products raises ex vivo interleukin-1beta secretion in hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum 46 10 (2002) 2794-2803
20. Takada K., Aksentijevich I., Mahadevan V., Dean J.A., Kelley R.I., and Kastner D.L. Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum 48 9 (2003) 2645-2651
21. Arkwright P.D., McDermott M.F., Houten S.M., et al. Hyper IgD syndrome (HIDS) associated with in vitro evidence of defective monocyte TNFRSF1A shedding and partial response to TNF receptor blockade with etanercept. Clin. Exp. Immunol. 130 3 (2002) 484-488
22. Bodar E.J., van der Hilst J.C., Drenth J.P., van der Meer J.W., and Simon A. Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model. Neth. J. Med. 63 7 (2005) 260-264
23. Schneiders M.S., Houten S.M., Turkenburg M., Wanders R.J., and Waterham H.R. Manipulation of isoprenoid biosynthesis as a possible therapeutic option in mevalonate kinase deficiency. Arthritis Rheum 54 7 (2006) 2306-2313
24. Simon A., Drewe E., van der Meer J.W., et al. Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clin. Pharmacol. Ther. 75 5 (2004) 476-483
25. Hoffmann G.F., Charpentier C., and Mayatepek E. Clinical and biochemical phenotype in 11 patients with mevalonic aciduria. Pediatrics 91 (1993) 915-921
26. Istvan E.S. Structural mechanism for statin inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Am. Heart J. 144 6 Suppl. (2002) S27-S32
27. Istvan E. Statin inhibition of HMG-CoA reductase: a 3-dimensional view. Atheroscler. Suppl. 4 1 (2003) 3-8
28. Istvan E.S., and Deisenhofer J. The structure of the catalytic portion of human HMG-CoA reductase. Biochim. Biophys. Acta 1529 1-3 (2000) 9-18
29. Lennernas H., and Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin. Pharmacokinet. 32 5 (1997) 403-425
30. Jones P., Kafonek S., Laurora I., and Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am. J. Cardiol. 81 5 (1998) 582-587
31. Jones P.H., Davidson M.H., Stein E.A., et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am. J. Cardiol. 92 2 (2003) 152-160
32. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 333 20 (1995) 1301-1307
33. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 20 (1998) 1615-1622
34. Sever P.S., Dahlof B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 9364 (2003) 1149-1158
35. Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman G.A., Neil H.A., Livingstone S.J., et al. CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicenter randomised placebo-controlled trial. Lancet 364 9435 (2004) 685-696
36. Prosser L.A., Stinnett A.A., Goldman P.A., et al. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Ann. Intern. Med. 132 10 (2000) 769-779
37. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 8934 (1994) 1383-1389
38. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. 335 14 (1996) 1001-1009
39. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N. Engl. J. Med. 339 19 (1998) 1349-1357
40. Tonkin A.M., Colquhoun D., Emberson J., et al. Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study. Lancet 356 9245 (2000) 1871-1875
41. Shepherd J., Blauw G.J., Murphy M.B., et al. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360 9346 (2002) 1623-1630
42. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 9326 (2002) 7-22
43. Shepherd J. Who should receive a statin these days? Lessons from recent clinical trials. J. Intern. Med. 260 4 (2006) 305-319
44. Bellosta S., Ferri N., Bernini F., et al. Non-lipid-related effects of statins. Ann. Med. 32 (2000) 164-176
45. Chan K.K., Oza A.M., and Siu L.L. The statins as anticancer agents. Clin. Cancer Res. 9 1 (2003) 10-19
46. Weber M.S., Youssef S., Dunn S.E., et al. Statins in the treatment of central nervous system autoimmune disease. J. Neuroimmunol. 178 1-2 (2006) 140-148
47. Aprahamian T., Bonegio R., Rizzo J., et al. Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model. J. Immunol. 177 5 (2006) 3028-3034
48. Sena A., Pedrosa R., and Graca Morais M. Therapeutic potential of lovastatin in multiple sclerosis. J. Neurol. 250 6 (2003) 754-755
49. Vollmer T., Key L., and Durkalski V. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363 15 (2004) 1607-1608
50. Peng X., Jin J., Giri S., et al. Immunomodulatory effects of 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors, potential therapy for relapsing remitting multiple sclerosis. J. Neuroimmunol. 178 1-2 (2006) 130-139
51. McCarey D.W., McInnes I.B., and Madhok R. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 363 9426 (2004) 2015-2021
52. Thomsen R.W., Hundborg H.H., Johnsen S.P., et al. Statin use and mortality within 180 days after bacteremia: a population-based cohort study. Crit. Care Med. 34 4 (2006) 1080-1086
53. Hackam D.G., Mamdani M., Li P., and Redelmeier D.A. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet 367 9508 (2006) 413-418
54. Kruger P., Fitzsimmons K., Cook D., Jones M., and Nimmo G. Statin therapy is associated with fewer deaths in patients with bacteraemia. Intensive Care Med. 32 1 (2006) 75-79
55. Almog Y., Shefer A., and Novack V. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 110 (2004) 880-885
56. Liappis A.P., Kan V.L., Rochester C.G., and Simon G.L. The effect of statins on mortality in patients with bacteremia. Clin. Infect. Dis. 33 (2001) 1352-1357
57. Mönkkönen H., Lehenkari P.P., Kellinsalmi M., et al. A new mechanism of action for bisphosphonates: Apppi dedicated cytotoxicity of N-BPs. Bone 34 (2004) S66-S67
58. Swanson K.M., and Hohl R.J. Anti-cancer therapy: targeting the mevalonate pathway. Curr. Cancer Drug Targets 6 1 (2006) 15-37
59. Dunford J.E., Thompson K., Coxon F.P., et al. Structure-activity relationships for inhibition of farnesy diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Ther. 296 (2001) 235-242
60. Coxon J.P., Oades G.M., Kirby R.S., and Colston K.W. Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. BJU Int. 94 (2004) 164-170
61. Denoyelle C., Hong L., Vannier J.P., Soria J., and Soria C. New insights into the action of zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects. Br. J. Cancer 88 (2003) 1631-1640
62. Sawada K., Morishige K., Tahara M., et al. Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of Rho. Cancer Res. 62 (2002) 6015-6020
63. Shipman C.M., Rogers M.J., Apperley J.F., Russell R.G.G., and Croucher P.I. Bisphosphonate induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br. J. Haematol. 98 (1997) 665-672
64. Fromigue O., Lagneaux L., and Body J.J. Bisphosphonates induce breast cancer cell death in vitro. J. Bone Miner. Res. 15 (2000) 2211-2221
65. Senaratne S.G., Pirianov G., Mansi J.L., Arnett T.R., and Colston K.W. Bisphosphonates induce apoptosis in human breast cancer cell line. Br. J. Cancer 82 (2000) 1459-1468
66. Green J.R., and Glezardin P. Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis. Am. J. Clin Oncol. 25 6 Suppl. 1 (2002) S3-S9
67. Gober H.J., Kistowska M., Angman L., Jenö P., Mori L., and De Libero G. Human T cell receptor cells recognize endogenous mevalonate metabolites in tumor cells. J. Exp. Med. 197 (2003) 163-168
68. Morgillo F., and Lee H.Y. Lonafarnib in cancer therapy. Expert Opin. Investig. Drugs 15 6 (2006) 709-719
69. Basso A.D., Kirschmeier P., and Bishop W.R. Lipid posttranslational modifications. Farnesyl transferase inhibitors. J. Lipid Res. 47 1 (2006) 15-31
70. Mesa R.A. Tipifarnib: farnesyl transferase inhibition at a crossroads. Expert Rev. Anticancer Ther. 6 3 (2006) 313-319
71. Feldman E.J. Farnesyltransferase inhibitors in myelodysplastic syndrome. Curr. Hematol. Rep. 4 3 (2005) 186-190
72. Peterson Y.K., Kelly P., Weinbaum C.A., and Casey P.J. A novel protein geranylgeranyltransferase-I inhibitor with high potency, selectivity, and cellular activity. J. Biol. Chem. 281 18 (2006) 12445-12450
73. El Oualid F., Cohen L.H., van der Marel G.A., and Overhand M. Inhibitors of protein: geranylgeranyl transferases. Curr. Med. Chem. 13 20 (2006) 2385-2427
74. Lobell R.B., Omer C.A., Abrams M.T., et al. Evaluation of farnesyl: protein transferase and geranylgeranyl : protein transferase inhibitor combinations in preclinical models. Cancer Res 61 24 (2001) 8758-8768
75. Peterson Y.K., Kelly P., Weinbaum C.A., and Casey P.J. A novel protein geranylgeranyltransferase-I inhibitor with high potency, selectivity, and cellular activity. J. Biol. Chem. 281 18 (2006) 12445-12450
76. Liao J.K. Isoprenoids as mediators of the biological effects of statins. J. Clin. Invest. 110 3 (2002) 285-288
77. Endres M., Laufs U., Huang Z., et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. U. S. A. 95 15 (1998) 8880-8885
78. Yang Z., Kozai T., van der Loo B., et al. HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins. J. Am. Coll. Cardiol. 36 5 (2000) 1691-1697
79. Essig M., Nguyen G., Prie D., Escoubet B., Sraer J.D., and Friedlander G. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. Circ. Res. 83 7 (1998) 683-690
80. Hernandez-Perera O., Perez-Sala D., Navarro-Antolin J., et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J. Clin. Invest. 101 12 (1998) 2711-2719
81. Crisby M., Nordin-Fredriksson G., Shah P.K., Yano J., Zhu J., and Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 103 7 (2001) 926-933
82. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285 13 (2001) 1711-1718
83. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 350 15 (2004) 1495-1504
84. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 97 15 (1998) 1440-1445
85. Waehre T., Damas J.K., Gullestad L., et al. Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease. J. Am. Coll. Cardiol. 41 9 (2003) 1460-1467
86. Waehre T., Yndestad A., Smith C., et al. Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors. Circulation 109 16 (2004) 1966-1972
87. Rezaie-Majd A., Maca T., Bucek R.A., et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler. Thromb. Vasc. Biol. 22 7 (2002) 1194-1199
88. Zineh I., Luo X., Welder G.J., et al. Modulatory effects of atorvastatin on endothelial cell-derived chemokines, cytokines, and angiogenic factors. Pharmacotherapy 26 3 (2006) 333-340
89. Peng X., Jin J., Giri S., et al. Immunomodulatory effects of 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors, potential therapy for relapsing remitting multiple sclerosis. J. Neuroimmunol. 178 1-2 (2006) 130-139
90. Wojciak-Stothard B., Williams L., and Ridley A.J. Monocyte adhesion and spreading on human endothelial cells is dependent on Rho-regulated receptor clustering. J. Cell Biol. 145 6 (1999) 1293-1307
91. Yoshida M., Sawada T., and Ishii H. HMG-CoA reductase inhibitor modulates monocyte endothelial interaction under physiological flow condition in vitro: involvement of Rho GTPase-dependent mechanism. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1165-1171
92. Kwak B., Mulhaupt F., Veillard N., Pelli G., and Mach F. The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells. Swiss Med. Wkly. 131 3-4 (2001) 41-46
93. Kwak B., Mulhaupt F., Myit S., and Mach F. Statins as a newly recognized type of immunomodulator. Nat. Med. 6 12 (2000) 1399-1402
94. Mach F. Statins as immunomodulatory agents. Circulation 109 21 Suppl. 1 (2004) II15-II17
95. Ghittoni R., Patrussi L., Pirozzi K., et al. Simvastatin inhibits T-cell activation by selectively impairing the function of Ras superfamily GTPases. FASEB J. 19 6 (2005) 605-607
96. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F., and Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 100 3 (1999) 230-235
97. Albert M.A., Danielson E., Rifai N., and Ridke P.M. PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 286 1 (2001) 64-70 Jul. 4
98. Ridker P.M., Rifai N., Clearfield M., et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N. Engl. J. Med. 344 26 (2001) 1959-1965
99. Ridker P.M., Cannon C.P., Morrow D., Rifai N., Rode L.M., McCabe C.H., et al. C-reactive protein levels and outcomes after statin therapy. N. Engl. J. Med. 352 1 (2005) 20-28
100. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291 9 (2004) 1071-1080
101. Kobashigawa J.A., Katznelson S., Laks H., et al. Effect of pravastatin on outcomes after cardiac transplantation. N. Engl. J. Med. 3 33 (10) (1995) 621-627
102. Sugiyama M., Kodama T., Konishi K., Abe K., Asami S., and Oikawa S. Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells. Biochem. Biophys. Res. Commun. 271 3 (2000) 688-692
103. Maeda T., Matsunuma A., Kawane T., and Horiuchi N. Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem. Biophys. Res. Commun. 280 (2001) 874-877
104. Viereck V., Grundker C., Blaschke S., Frosch K.H., Schoppet M., Emons G., et al. Atorvastatin stimulates the production of osteoprotegerin by human osteoblasts. J. Cell Biochem. 96 6 (2005) 1244-1253
105. Maeda T., Matsunuma A., Kurahashi I., Yanagawa T., Yoshida H., and Horiuchi N. J. Cell Biochem. 92 3 (2004) 458-471
106. Grasser W.A., Baumann A.P., Petras S.F., Harwood H.J., Devalaraja R., Renkiewicz R., et al. Regulation of osteoclast differentiation by statins. J. Musculoskelet. Neuronal Interact. 3 1 (2003) 53-62
107. Fisher J.E., Rogers M.J., Halasy J.M., et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc. Natl. Acad. Sci. U. S. A. 96 1 (1999) 133-138
108. Chan K.A., Andrade S.E., Boles M., et al. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 355 9222 (2000) 2185-2188
109. Meier C.R., Schlienger R.G., Kraenzlin M.E., Schlegel B., and Jick H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 283 24 (2000) 3205-3210
110. Scranton R.E., Young M., Lawler E., Solomon D., Gagnon D., and Gaziano J.M. Statin use and fracture risk: study of a US veterans population. Arch. Intern. Med. 165 17 (2005) 2007-2012
111. Reid I.R., Tonkin A., and Cannon C.P. Comparison of the effects of pravastatin and atorvastatin on fracture incidence in the PROVE IT-TIMI 22 trial-secondary analysis of a randomized controlled trial. Bone 37 2 (2005) 190-191
112. Reid I.R., Hague W., Emberson J., Baker J., Tonkin A., Hunt D., et al. Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. Lancet 357 9255 (2001) 509-512 Feb. 17
113. van Staa T.P., Wegman S., de Vries F., Leufkens B., and Cooper C. Use of statins and risk of fractures. JAMA 285 14 (2001) 1850-1855
114. Denoyelle C., Vasse M., Korner M., et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 22 8 (2001) 1139-1148
115. Poynter J.N., Gruber S.B., Higgins P.D., et al. Statins and the risk of colorectal cancer. N. Engl. J. Med. 352 21 (2005) 2184-2192
116. Graaf M.R., Beiderbeck A.B., Egberts A.C., Richel D.J., and Guchelaar H.J. The risk of cancer in users of statins. J. Clin. Oncol. 22 12 (2004) 2388-2394
117. Boudreau D.M., Gardner J.S., Malone K.E., Heckbert S.R., Blough D.K., and Daling J.R. The association between 3-hydroxy-3-methylglutaryl coenzyme A inhibitor use and breast carcinoma risk among postmenopausal women: a case-control study. Cancer 100 11 (2004) 2308-2316
118. DeKosky S.T. Statin therapy in the treatment of Alzheimer disease: what is the rationale? Am. J. Med. 118 Suppl. 12A (2005) 48-53
119. Miida T., Takahashi A., Tanabe N., and Ikeuchi T. Can statin therapy really reduce the risk of Alzheimer's disease and slow its progression?. Curr. Opin. Lipidol. 16 6 (2005) 619-623
120. Jick H., Zornberg G.L., Jick S.S., Seshadri S., and Drachman D.A. Statins and the risk of dementia. Lancet 356 9242 (2000) 1627-1631
121. Rockwood K., Kirkland S., Hogan D.B., et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch. Neurol. 59 2 (2002) 223-227
122. Wolozin B., Kellman W., Ruosseau P., Celesia G.G., and Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57 10 (2000) 1439-1443
123. Sparks D.L., Sabbagh M., and Connor D. Statin therapy in Alzheimer's disease. Acta Neurol. Scand., Suppl. 185 (2006) 78-86
124. Wakchoure S., Merrell M.A., Aldrich W., et al. Bisphosphonates inhibit the growth of mesothelioma cells in vitro and in vivo. Clin. Cancer Res. 12 1 (2006) 2862-2868
125. Kubista B., Trieb K., Sevelda F., Toma C., Arrich F., Heffeter P., Elbling L., et al. Anticancer effects of zoledronic acid against human osteosarcoma cells. J. Orthop. Res. 24 6 (2006) 1145-1152 Jun.
126. Goffinet M., Thoulouzan M., Pradines A., et al. Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells. BMC Cancer 6 (2006) 60
127. Kawashima H., Ogose A., Hotta T., et al. Effect of incadronate on proliferation of mesenchymal tumor cells with or without activated Ras mutation. J. Exp. Clin. Cancer Res. 24 4 (2005) 617-624
128. Wada A., Fukui K., Sawai Y., et al. Pamidronate induced anti-proliferative, apoptotic, and anti-migratory effects in hepatocellular carcinoma. J. Hepatol. 44 1 (2006) 142-150
129. Iguchi K., Nakano T., Usui S., and Hirano K. Incadronate inhibits aminopeptidase N expression in prostatic PC-3 cells. Cancer Lett. 237 2 (2006) 223-233 18
130. Evdokiou A., Labrinidis A., Bouralexis S., Hay S., and Findlay D.M. Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis. Bone 33 2 (2003) 216-228
131. Jagdev S.P., Coleman R.E., Shipman C.M., Rostami A.H., and Croucher P.I. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br. J. Cancer 84 8 (2001) 1126-1134
132. Shipman C.M., Croucher P.I., Russell R.G., Helfrich M.H., and Rogers M.J. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res. 58 23 (1998) 5294-5297
133. Tassone P., Tagliaferri P., Viscomi C., et al. Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br. J. Cancer 88 (2003) 1971-1978